| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03398837 Details | 2021-03-29 Interventional | 3 | 365 | Dronabinol Lenabasum Scleroderma, Di… Scleroderma, Sy… Sclerosis Diffuse Cutaneo… | Sponsor terminated open-label extension - | |||
| NCT03890341 Details | 2021-03-26 Interventional | 1 | 0 | Betadex Drospirenone Drospirenone an… Ethinyl Estradi… Midazolam Healthy | Stopped due to a strategic decision. - | |||
| NCT02353754 Details | 2021-03-26 Interventional | 4 | 12 | Bupivacaine Morphine Pain | Slow enrollment. None of the subjects received EXPAREL. - | |||
| NCT04683237 Details | 2021-03-25 Interventional | 2/3 | 0 | Liraglutide Megestrol Megestrol Aceta… Endometrial Hyp… Hyperplasia Infertility Atypical Endome… Fertility Issue… Obese | Based on our latest research results, we will revise the protocol and design a better study.
Since no participants are enrolled till now, we withdraw this study. - | |||
| NCT00257192 Details | 2021-03-25 Interventional | 3 | 284 | Ziprasidone Schizophrenia | Please see Detailed Description for termination reason. The AE tables were amended to incorporate previously unreported AEs that were found during an independent audit and verified by the investigators. | |||
| NCT03042312 Details | 2021-03-24 Interventional | 2 | 71 | Pluvicto Prostatic Neopl… Metastatic Cast… | Recruitment was stopped before the target sample size was achieved. The study began on 05-Jul-17 as an Investigator Initiated Trial and sponsorship was transferred to Endocyte on 01-Jun-18. Recruitment was stopped before the target sample size was achieved based on strategic considerations. | |||
| NCT01146561 2010-019012-21 Details | 2021-03-23 Interventional | 2 | 2 | Tanezumab Pancreatitis Pancreatitis, C… Chronic Pancrea… | See termination reason in detailed description. Due to FDA clinical hold, the study was prematurely terminated with only 2 participants were enrolled and randomized to placebo treatment and hence, efficacy and pharmacokinetic analysis was not performed. | |||
| NCT02750514 Details | 2021-03-22 Interventional | 2 | 295 | Dasatinib Ipilimumab Linrodostat Nivolumab Relatlimab Carcinoma, Non-… Advanced Cancer | The standard of care for the patient population changed and we were unable to accrue any
longer. This study was terminated early by sponsor for reasons unrelated to safety. | |||
| NCT00055575 Details | 2021-03-22 Interventional | 2 | 197 | Butylscopolammo… Scopolamine Bipolar Disorde… Depression Depressive Diso… Mood Disorders Bipolar Depress… Healthy Unipolar Depres… | - - | |||
| NCT04495010 2020-000070-16 Details | 2021-03-19 Interventional | 2 | 0 | Ipilimumab Nivolumab Melanoma | Business objectives have changed - | |||
| NCT00130312 NCT00342238 Details | 2021-03-19 Interventional | 4 | 968 | Glucuronyl gluc… Diabetic Nephro… Kidney Diseases Diabetic Nephro… | No difference in protein excretion at 6&12 months. No safety issues. - | |||
| NCT03992326 Details | 2021-03-18 Interventional | 1 | 6 | Cyclophosphamid… Fludarabine Interleukin-2 Neoplasms Solid Tumor, Ad… | Internal competitive study that is open - | |||
| NCT03003195 Details | 2021-03-18 Interventional | 2 | 0 | Monatide (IMS 3… Neoplasm Metast… Neoplasms Neoplasms by Si… Neoplasms, Seco… Metastatic Canc… | Lack of Funding - | |||
| NCT02272699 Details | 2021-03-18 Interventional | 2/3 | 0 | Nimotuzumab Paclitaxel Carcinoma Carcinoma, Squa… Esophageal Squa… | Because there are questions about adjuvant radiotherapy in this study, the clinical trial is
under re-design. - | |||
| NCT01093638 Details | 2021-03-18 Interventional | 2 | 33 | Insulin Premature Birth Premature Birth… | - - | |||
| NCT02605694 2015-004729-15 Details | 2021-03-17 Interventional | 2 | 0 | Prednisone Rituximab Lymphoma Lymphoma, Folli… | Sponsor is focusing on studies which can enable registration of duvelisib - | |||
| NCT02576275 Details | 2021-03-17 Interventional | 3 | 0 | Bendamustine Hy… Rituximab Leukemia, Lymph… Lymphoma Lymphoma, B-Cel… Lymphoma, Folli… Lymphoma, Non-H… Follicular Lymp… Indolent Non-Ho… Marginal Zone L… Small Lymphocyt… | The scope of the program has been reduced to focus resources on studies which can potentially
enable the registration of duvelisib. - | |||
| NCT00610935 Details | 2021-03-17 Interventional | 3 | 82 | Peramivir Influenza, Huma… Influenza | This study was terminated for administrative reasons. The study was terminated at the discretion of the Sponsor after 82 of the planned 600 subjects were enrolled. The reason for study termination was to allow the Sponsor to focus development efforts on a more concentrated formulation which would also allow evaluation of higher doses of peramivir administered intramuscularly. | |||
| NCT03723824 Details | 2021-03-16 Interventional | 4 | [3 Refs] | 14 | Elbasvir-grazop… Grazoprevir Communicable Di… Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Hepatitis, Chro… Infections Chronic Hepatit… Kidney Transpla… Liver Transplan… | COV-19 pandemic - | ||
| NCT03549689 Details | 2021-03-15 Interventional | 2 | 0 | Dolutegravir Lamivudine Tenofovir Bone Diseases, … HIV-1-infection HIV/AIDS Osteopenia | Withdrawn by drug manufacturer - |